
GE HealthCare launches new advanced digital X-ray system to enable access and increase efficiency in high throughput settings
X-ray exams often serve as the entry point to diagnostic imaging, accounting for 60% of all imaging studies conducted, resulting in an ever-increasing workload for radiologists and technologists2 3. This increased demand, combined with acute staffing challenges where 80% of healthcare organizations are short-staffed and radiology technologists have the highest vacancies3, high burnout levels and work-related injuries, creates critical barriers to providing timely, effective diagnostic imaging for patients in need of X-ray imaging.
GE HealthCare's new Definium Pace Select ET solves for many of these challenges by automating manual, repetitive steps and helping to reduce physical strain. The system leverages AI to ensure accurate patient positioning and consistent image quality across various clinical conditions while streamlining the technologist workflow to maximize the patient experience and throughput.
'Burdened with the stress and pressure to keep radiology departments running smoothly and profitably, we aim to empower technologists with a system that consistently makes the first image count,' said Sharad Sharma, Global General Manager, X-ray, at GE HealthCare. 'With its advanced digital capabilities and automation, Definium Pace Select ET allows technologists of all experience levels to deliver consistent high-quality images to serve the full range of anatomies and patient populations.'
Easy-to-use features allow technologists to focus on patient care
Building on the trusted Definium platform from GE HealthCare, the Definium Pace Select ET system brings advanced automation and workflow features to a flexible, floor-mounted system with elevating table, in-room exam control, and common user interface to assist technologists.
'This launch reinforces our commitment to provide accessible, efficient, and high-quality care for patients, while alleviating stress from the technologist's workday by minimizing repetitive tasks and automating steps,' said Jyoti Gupta, PhD, President & CEO of Women's Health and X-ray at GE HealthCare. 'We remain dedicated to advancing our technology through transformative digital and AI-enabled capabilities that will remove barriers to timely and effective diagnostic imaging for any patient in need of X-ray imaging.'
The Definium Pace Select ET system brings the same high image quality typically seen in more expensive overhead tube suspension (OTS) systems to the affordability focused floor-mounted market. Designed and developed with extensive customer feedback, the system brings:
Advanced automation to reduce workflow steps and physically demanding movements for technologists, potentially minimizing work-related injuries.
to reduce workflow steps and physically demanding movements for technologists, potentially minimizing work-related injuries. Image variability reduction through the AI-enabled Helix™ Advanced Image Processing to provide consistent high-quality images.
through the AI-enabled Helix™ Advanced Image Processing to provide consistent high-quality images. Prevention of errors before they occur through automated positioning, protocol selection, patient size (body habitus), and collimation via the Intelligent Workflow Suite, and a quality check prior to radiation exposure.
To learn more about the new X-ray system, visit gehealthcare.com.
About GE HealthCare Technologies Inc.
GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits.
GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™.
Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com for more information.
_______________________________
1 510(k) cleared. Not CE marked. Cannot be placed on the market or put into service or used with human beings until it has been made to comply with CE marking and/or regulatory approval. Not all features available in all markets.
2 MV 2019 X-ray CR / DR Market Outlook Report) page 9, 37
3 Pearson, Dave. 'Radiology techs in especially high demand as 85% of hospitals seek 'allied' health workers', radiologybusiness.com, 23 Oct. 22.
Expand
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Qualcomm (QCOM) Q2 Earnings Preview: What to Expect From Upcoming Report
July 29- Qualcomm (NASDAQ:QCOM) will reveal Q3 FY2025 results on July 30 after the market close. Wall Street expects adjusted EPS of $2.71, a 16.3% rise from a year ago, and revenue of $10.34 billion, up 10.1%. Investors eye the report amid worries that Apple (NASDAQ:AAPL) will shift to in?house modem chips next year, potentially trimming Qualcomm's handset chip sales. Smartphone market pressures and tariff risks in China also weigh on sentiment. Warning! GuruFocus has detected 6 Warning Signs with QCOM. Still, analysts note Qualcomm's growing footprint in IoT, automotive and edge AI. Bernstein's Stacy Rasgon keeps a Buy rating with a $185 target, calling Qualcomm heavily out of favor yet undervalued given its diverse product lineup and expected double?digit earnings growth. He says it's worth keeping on investors' radar. KeyBanc envisions wider semiconductor power with the help of demand in A as well as new product ramps. It predicts positive prospects of Qualcomm in Q3 but warns that second part of 2025 can have backdrafts due to Apple moving to other modems and sluggish Android market in China. The results will help to understand what degree of offset of challenges related to the handset is possible to be achieved by the divisions, which are engaged with non-smartphone, and whether Qualcomm will be able to quality its growth trend up to the end of the year. Based on the one year price targets offered by 30 analysts, the average target price for Qualcomm Inc is $177.50 with a high estimate of $225.00 and a low estimate of $140.00. The average target implies a upside of +10.21% from the current price of $161.05. Based on GuruFocus estimates, the estimated GF Value for Qualcomm Inc in one year is $160.62, suggesting a downside of -0.27% from the current price of $161.05. Gf value is Gurufocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. For deeper insights, visit the forecast page. This article first appeared on GuruFocus.
Yahoo
8 minutes ago
- Yahoo
Vor Biopharma (VOR) Jumps 10% on Addition of 2 CEOs to Board
We recently published . Vor Biopharma Inc. (NASDAQ:VOR) is one of the best-performing stocks on Monday. Vor Biopharma extended its winning streak to a fourth consecutive day on Monday, jumping 10 percent to close at $2.42 apiece and bucking the decline in the overall healthcare sector, as investors continued to load up positions following the addition of two CEOs in its board. Early last week, Vor Biopharma Inc. (NASDAQ:VOR) announced the addition of Alexander Cumbo and Michel Detheux to its board of directors, sparking confidence among investors amid ongoing efforts to strengthen leadership and strategic direction. Cumbo currently serves as president and CEO of Solid Biosciences. He was also the founding CEO of AavantiBio and brings more than 30 years of commercial and executive leadership, including nearly eight years at Sarepta Therapeutics, where he most recently served as Executive Vice President and Chief Commercial Officer. Meanwhile, Detheux is the president and CEO of iTeos Therapeutics. Under his leadership, iTeos raised over $1 billion in capital, completed a successful IPO, and secured a landmark $2 billion partnership with GSK to co-develop and commercialize the company's lead anti-TIGIT antibody. Copyright: nimon / 123RF Stock Photo In a statement, Vor Biopharma Inc. (NASDAQ:VOR) said that Cumbo and Detheux's addition is invaluable as the company advances telitacicept through late-stage development and expands its long-term vision to bring transformative therapies to patients with autoimmune disease. While we acknowledge the potential of VOR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 minutes ago
- Yahoo
Super Micro (SMCI) Rallies 10.2% as US Freezes Export Curbs to China
We recently published . Super Micro Computer, Inc. (NASDAQ:SMCI) is one of the best-performing stocks on Monday. Super Micro jumped for a fourth straight day on Monday, adding 10.24 percent to close at $60.05 apiece as investors cheered President Donald Trump's decision to freeze export restrictions on technology products to China as Washington and Beijing resume trade negotiations. The US and China will meet in Stockholm for a third round of trade talks on Monday, following previous meetings in Geneva and London. Known for its AI-focused server systems, Super Micro Computer, Inc. (NASDAQ:SMCI) is one of the companies benefiting from increased technology spending this year. Year-to-date, its stock has gone up by almost 100 percent as more companies globally build large artificial intelligence workloads. Copyright: wavebreakmediamicro / 123RF Stock Photo In other developments, Super Micro Computer, Inc. (NASDAQ:SMCI) is set to announce the results of its earnings performance for the fourth quarter of fiscal year 2025 after market close on August 5. An investor call will be held on the same day to elaborate on the results. While we acknowledge the potential of SMCI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Sign in to access your portfolio